Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability of Nirmatrelvir/Ritonavir FDC Formulations
NCT05525910Phase 1Completed
- Sponsor
- Pfizer
- Start
- Aug 2022
- Primary completion
- Nov 2022
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of Nirmatrelvir in coronavirus disease 2019 (COVID-19) (5 arms), sponsored by Pfizer. Primary endpoints: Area Under the Curve from Time Zero to Infinity (AUCinf) for Nirmatrelvir, Area Under the Curve from Time Zero to Last Quantifiable Concentration (AUClast) for Nirmatrelvir and 4 more. Started Aug 2022; status: completed.
02
Drugs
Nirmatrelvir
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05525910.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05525910.